A pivotal phase ll/lll trial evaluating efficacy of QBM-001 for the treatment of young children with a rare autistic spectrum disorder

Trial Profile

A pivotal phase ll/lll trial evaluating efficacy of QBM-001 for the treatment of young children with a rare autistic spectrum disorder

Planning
Phase of Trial: Phase II/III

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs QBM-001 (Primary)
  • Indications Pervasive child development disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Q BioMed
  • Most Recent Events

    • 01 Feb 2018 New trial record
    • 30 Jan 2018 According to a Q BioMed media release, the company anticipates initiating this trial in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top